Referred to the House Committee on Energy and Commerce.
This bill dissolves the National Institute of Allergy and Infectious Diseases (NIAID) and creates three separate institutes: the National Institute of Allergic Diseases, the National Institute of Infectious Diseases, and the National Institute of Immunologic Diseases. It amends the Public Health Service Act to add these institutes, transfers related statutory authorities, provides for orderly transitions, and changes appointment rules so each new institute director is appointed by the President with Senate advice and consent to a five‑year term (one reappointment allowed).
Progressives emphasize risk of politicization via presidential appointments
Mid-sized, targeted reorganization can advance in the House if majority supports it; may face internal committee and stakeholder pushback.
This bill dissolves the National Institute of Allergy and Infectious Diseases (NIAID) and creates three separate institutes: the National Institute of Allergic Diseases, the National Institute of Infectious Diseases, and the National Institute of Immunologic Diseases.
It amends the Public Health Service Act to add these institutes, transfers related statutory authorities, provides for orderly transitions, and changes appointment rules so each new institute director is appointed by the President with Senate advice and consent to a five‑year term (one reappointment allowed).
The existing NIAID director position is terminated and the NIH Director oversees the institutes until directors are appointed; numerous conforming statutory amendments are included.
Organizational, low-cost bill with political overtones; plausible House traction but low Senate odds absent broad bipartisan compromise or inclusion in larger vehicle.
How solid the drafting looks.
Progressives emphasize risk of politicization via presidential appointments
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize risk of politicization via presidential appointments
Likely skeptical.
Supporters of robust, science-driven public health may worry this structural split could politicize leadership and fragment interdisciplinary research.
Some progressives might see potential for better focus on allergic, infectious, or immunologic research but will request strong safeguards.
Pragmatic and mixed.
A moderate would weigh possible management and accountability improvements against likely costs and coordination problems.
Support depends on clear transition planning, cost estimates, and protections for research continuity.
Generally favorable.
Mainstream conservatives are likely to view splitting a large institute as increasing accountability and reducing bureaucratic concentration.
They will welcome presidential appointment authority and see potential for improved oversight, while some may demand budget neutrality.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Organizational, low-cost bill with political overtones; plausible House traction but low Senate odds absent broad bipartisan compromise or inclusion in larger vehicle.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize risk of politicization via presidential appointments
Organizational, low-cost bill with political overtones; plausible House traction but low Senate odds absent broad bipartisan compromise or…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for NIH Reform Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.